Amber Tong – Page 74 – Endpoints News

about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW

Amber Tong on LinkedIn

author articles

Diagnostic champ Roche buys its way into the RET title fight with Eli Lilly, paying $775M in cash to Blueprint

5 years ago

CytoDyn shares slammed as BLA filing for leronlimab in HIV hits a wall

5 years ago

Covid-19 roundup: CanSino eyes more overseas PhIII sites as Canada trial reportedly stalls; Indian drugmaker surges ...

5 years ago

China's BeiGene now has $5B+ cash in its coffers. How's the Amgen-partnered biotech going to spend it?

5 years ago

AstraZeneca signs computational drug discovery collaboration; J&J-partnered Fate cleared for the clinic

5 years ago

Ophthalmic drugs, cancer cell therapies attract $340M+ on two HKEX biotech debuts

5 years ago

A new venture fund amid a pandemic? In the Nordics? Eir Ventures brings it on with €76M first close

5 years ago

Biopharma companies pledge $1B to fund antibiotics R&D as field shrivels; Four biotechs hunt $797M+

5 years ago

Forbion spotlights late-stage plays, carves out new €250M growth fund

5 years ago

Out to revive R&D, a resurgent Sanofi pays $150M cash to partner up with a pioneering protein degradation player

5 years ago

Zai Lab inks China deal with Turning Point with $25M upfront; Xencor, Atreca team up on bispecifics

5 years ago

Singular focus on ROR1 earns VelosBio $137M to fund PhI ADC and other programs

5 years ago

'Fundamentally different' from Portola, Dutch biotech lands €32M to steer anti-anticoagulant through the clinic

5 years ago

John Reed brings NK cells into Sanofi's CD38 rivalry with J&J — and offers thumbs up for Kiadis' new focus

5 years ago

RA Capital doubles down on Siddhartha Mukherjee's vision for a new cell engineering approach, leading Vor's $110M ...

5 years ago

Covid-19 roundup: Squabbles with government delay Moderna’s PhIII — reports; Novavax secures largest Warp Speed ...

5 years ago

Immunomedics spells out PFS benefit of Trodelvy in mTNBC, hunting a full OK just weeks after accelerated approval

5 years ago

Covid-19 roundup: Teamed up with NIH, Regeneron launches PhIII prevention trial for antibody cocktail

5 years ago

Looking for 'external innovation,' Boehringer Ingelheim reserves $500M+ for new Shanghai hub

5 years ago

Novartis loses biosimilar appeal as court upholds a 31-year monopoly by Amgen's Enbrel

5 years ago

Armed with positive ALS data, Amylyx scores $30M in fresh funding to complete Alzheimer's PhII

5 years ago

New standard of care? FDA hands Pfizer, Merck KGaA an OK for Bavencio in bladder cancer

5 years ago

Rubius marks milestone in PhI/II as CFO departs; Owkin closes $70M Series A; The Carlyle Group bets on Indian CDMO

5 years ago

Covid-19 roundup: Vaccines will need to beat placebo by 50% to qualify for FDA OK; UK trial drops Kaletra

5 years ago

First page Previous page 71 72 737475 76 77 Next page Last page